Award Winning Paper
LimmaTech Biologics is very pleased to announce that the paper on the “Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial” received an award from The Swiss Society for Infectious Diseases in the category “clinical research in infectious diseases”.
We like to thank all the people involved in this achievement.
LimmaTech Biologics will be attending the 19th EUROCARB in Barcelona from 2 through 6 July 2017.
LimmaTech Biologics will be attending the Biobetters and Next-Generation Biologics: Innovative Strategies for Optimally Effective Therapies (A7) in Snowbird, USA from 22 through 26 January 2017.